Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer

Kevin A Nguyen; Alan Lee; Sagar A Patel; Arun Chakravorty; James B Yu; Amar U Kishan; Albert J Chang

doi:10.1001/jamanetworkopen.2020.17144

Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer

JAMA Netw Open. 2020 Sep 1;3(9):e2017144. doi: 10.1001/jamanetworkopen.2020.17144.

Authors

Kevin A Nguyen¹, Alan Lee¹, Sagar A Patel², Arun Chakravorty¹, James B Yu³, Amar U Kishan¹, Albert J Chang¹

Affiliations

¹ Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles.
² Department of Radiation Oncology, Emory University, Atlanta, Georgia.
³ Deparment of Radiation Oncology, Yale School of Medicine, New Haven, Connecticut.

Abstract

This cohort study examines trends in the use of brachytherapy, external beam radiotherapy, and stereotactic body radiation therapy for disease management in patients with localized prostate cancer and compares outcomes between these therapies.

Publication types

Comparative Study

MeSH terms

Aged
Brachytherapy / trends*
Humans
Kallikreins / blood
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Proportional Hazards Models
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood
Prostatic Neoplasms / pathology
Prostatic Neoplasms / radiotherapy*
Radiosurgery / trends*
Radiotherapy / trends
Radiotherapy Dosage
Risk
Survival Rate
Treatment Outcome

Substances

KLK3 protein, human
Kallikreins
Prostate-Specific Antigen

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States